Last reviewed · How we verify
NCT07129902: CM+ED+MOUD
Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department
NA trial testing Contingency Management in Opioid Use Disorder in 30 participants. Not yet recruiting.
1 October 2026
Quick facts
| Lead sponsor | University of Vermont |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 September 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Contingency Management
- Usual care as prescribed by the ED physicians
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
University of Vermont
Who can join
18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Project Summary The goal of this pilot clinical trial is to assess contingency management (CM) for increasing attendance at outpatient clinics after Medication for Opioid Use Disorder (MOUD) prescription and clinic referral occurred in the hospital Emergency Department (ED). * The researchers will compare usual care (UC)+CM to UC alone to see if 1) CM works to promote MOUD clinic attendance after discharge from the ED and 2) demonstrate feasibility of providing CM in the ED and outpatient MOUD clinic settings. * Researchers will randomize 30 adults who started MOUD in the ED into two conditions. These conditions consist of (A) UC alone: A referral to an outpatient buprenorphine or methadone provider with reminders from STAR program staff or (B) UC+CM: UC plus financial incentives dependent on MOUD clinic attendance to receive an MOUD prescription. The primary outcome of interest is the number of participants who receive their first MOUD prescription from the outpatient clinic after discharge from the ED in UC+CM compared to the UC-only condition. A secondary outcome will be the proportion of participants who kept attending outpatient MOUD treatment by the end of the 30-day study period between UC+CM and UC conditions. An exploratory outcome will be biochemically-verified illicit opioid abstinence measured at day 30.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07129902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Contingency Management
Trials testing the same drug.
- NCT07281378 — Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of · NA · not yet recruiting
- NCT07218471 — Cannabis Reduction and Functional Outcomes · NA · recruiting
- NCT07226596 — Non-Abstinence Outcomes in Methamphetamine Use Disorder · NA · recruiting
- NCT06432985 — Smoking Cessation CM for Veterans With or at Risk for Cancer · NA · recruiting
- NCT06304467 — CM for Patients With ALD After Liver Transplant · NA · active not recruiting
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other University of Vermont trials
Trials by the same sponsor.
- NCT07495098 — Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer · Phase 1 · not yet recruiting
- NCT07440641 — RE-FIT (Remote Exercise for Physical Function in WTC Responders With Prostate Cancer) · NA · not yet recruiting
- NCT06993129 — A Multi-Site Hybrid Type I Effectiveness-Implementation Randomized Trial of an Emergency Care Action Plan for Infants Wi · NA · not yet recruiting
- NCT07383727 — Readiness to Change and the Implementation of Home Modifications for Adults Over 60 · NA · not yet recruiting
- NCT06670079 — Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07129902 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Vermont
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07129902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing